Fisgatinib, an anti-FGFR4 inhibitor, demonstrated a degree of monotherapy activity, giving evidence of radiographic tumor reductions in 41% of FGF IHC-positive patients, with the majority having received prior TKI and with approximately one-third having received prior ICI [70]; however, as shown in a small study of four patients with FGF19+ HCC and no prior systemic therapy, in combination with CS1001, an anti-PD-L1 mAb, half the patients had a clinical response with a DCR of 100% [102]. This evidence concerns the gene CD274 and neoplasm.